Florman, Milan Kinkhabwala, Glyn Morgan, Mark S. Orloff,

Lewis Teperman, Samantha DeLair Background: End Stage Liver Disease (ESLD) is the 7th leading cause of patient mortality in the U.S. with 26,000 deaths annually. Hepatocellular carcinoma (HCC) accounts for an additional 18,000 deaths yearly, often occurring in the background of cirrhosis. Liver transplantation (LT) is curative, however only a minority of patients with ESLD and/or HCC are in receipt of this treatment. Aim: To evaluate utilization of palliative care services to patients with ESLD, not deemed eligible for LT, at a tertiary care center. Methods: A database was created following review of LT selection meetings at our center from 2007-2012. Suitable patients, who completed this website LT evaluation but were deemed

unsuitable for listing were identified and included in the analysis. Patients were excluded if their evaluation was incomplete, the patient was deceased, or did not have follow-up care at our institution following denial of listing. The medical chart of each patient was reviewed and relevant information retrieved. Results: There were a total of 116 patients in our cohort. The average interval between denial of LT listing and involvement of palliative care was 149 days. Mean survival was 137 days after denial of listing, Selumetinib clinical trial which excludes 19 patients (15.5%) with unknown date of death. 38 patients (32.8%) were hospitalized following denial, excluding admissions for palliative treatments. Comfort measures were initiated in all patients prior to death, though this occurred on date of death for 20 patients (17.2%). Following transplant denial, the mean number of hospital stays was

0.73 among the entire cohort and 2.66 among those with one or more stays. The mean inpatient length of stay was MCE公司 4 days among entire cohort and 15 days among patients with one or more stays. Nine patients (8%) required ICU care with an average LOS of 7.3 days. 69 patients (59.4%) received hospice care with an average LOS of 22 days. 29 patients (25%) had HCC and of those, 9 (31%) had palliative treatments. Advance directives were on file for 88 patients (75.9%). Conclusions: Palliative care was instituted shortly after removal from waitlist or denial of transplant candidacy in the majority of patients. One third of patients were hospitalized after denial and inpatient status was predictive of additional hospitalizations after denial. Further studies are needed to study how best to optimize care for patients with ESLD and avoid costly interventions that fail to improve outcomes or quality of life. Disclosures: The following people have nothing to disclose: Sean G. Kelly, Parul D. Agarwal Background: The Model for End-Stage Liver Disease (MELD) score, which estimates short-term mortality, determines priority for liver transplantation (LT).